Quarterly ResultMay 6, 2026, 07:27 AM
Lifecore Biomedical Q1 Revenue $23.19M, Net Loss $(14.98)M
AI Summary
Lifecore Biomedical reported a significant decrease in total revenues to $23.19 million for the three months ended March 31, 2026, down from $35.15 million in the comparable prior period. The company's net loss slightly increased to $(14.98) million, or $(0.43) per share. Despite the revenue decline, net cash provided by operating activities improved to $4.70 million, and the company saw positive developments in its legal matters, including the conclusion of an SEC investigation with no action and preliminary approval for a class action settlement.
Key Highlights
- Total revenues decreased to $23.19 million from $35.15 million.
- Net loss was $(14.98) million, compared to $(14.77) million in the prior period.
- Loss per share was $(0.43), a slight increase from $(0.42).
- Net cash provided by operating activities increased to $4.70 million from $1.20 million.
- SEC investigation concluded with no action taken against the company.
- Preliminary approval granted for class action settlement, expected to be covered by insurance.
- Investor dispute claims largely dismissed by the Court.
- Cash and cash equivalents increased to $20.79 million from $17.47 million.
Price Impact
More from LFCR